Foundations of Care

Strength training on Ozempic, Wegovy, and other GLP-1s

Sword Editorial Team

Footnotes

1

Neeland IJ, Linge J, Birkenfeld AL, et al. Changes in lean body mass with glucagon-like peptide-1–based therapies and mitigation strategies. Diabetes Obesity and Metabolism. 2024;26(Suppl 4):16–27. https://pubmed.ncbi.nlm.nih.gov/38937282/

2

Nauck MA. GLP-1 receptor agonists and lean body mass. The Lancet Diabetes & Endocrinology. 2024. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00272-9

3

Johnson B, Milstead M, Thomas O, et al. Nutrient intake patterns in adults using GLP-1 receptor agonists: a cross-sectional study. Frontiers in Nutrition. 2025. https://www.frontiersin.org/articles/10.3389/fnut.2025.1566498/full

4

Sword Health. Move Book of Business data. 2023.

Portugal 2020Norte 2020European UnionPlano de Recuperação e ResiliênciaRepública PortuguesaNext Generation EU